ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$8.82 USD
-0.16 (-1.78%)
Updated May 29, 2024 04:00 PM ET
After-Market: $8.80 -0.02 (-0.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
ARS Pharmaceuticals, Inc. [SPRY]
Reports for Purchase
Showing records 21 - 40 ( 40 total )
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Citizen Petition Underscores Potential; Approval Likely Despite Possible Delay
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Post-AdCom Discussions De-Risk Approval, Focus on Commercial Opportunity; Q1:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PADAC: neffy''s Benefits Outweigh the Risks, Supported by Unmet Need
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New Key Findings in Briefing Documents Introduce Risk Ahead of May 11 AdCom
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Highlights: Setting the Stage Ahead of neffy?s Upcoming AdCom
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Invite: Setting the Stage Ahead of neffy?s Upcoming AdCom
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA AdCom for neffy Set for May 11 Ahead of Mid-23 PDUFA
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
As The Dust Settles -- Sifting Through The Biotech Carnage, We See Opportunity
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Survey Underscores neffy''s Commercial Opportunity & Potential for Robust Uptake
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Invite: Shaking up the Epi Market with No-Needle Alternatives
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: ARS Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with an OUTPERFORM and $10 twelve-month PT.
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A